PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDeflazacort
Deflazacort
Deflazacort, Emflaza (deflazacort) is a small molecule pharmaceutical. Deflazacort was first approved as Emflaza on 2017-02-09. It is used to treat duchenne muscular dystrophy and inflammation in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Deflazacort, Emflaza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deflazacort
Tradename
Company
Number
Date
Products
EMFLAZAPTC TherapeuticsN-208684 RX2017-02-09
4 products, RLD, RS
EMFLAZAPTC TherapeuticsN-208685 RX2017-02-09
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
deflazacortANDA2025-01-17
deflazacort oral suspensionANDA2024-06-28
emflazaNew Drug Application2024-06-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
inflammationMP_0001845D007249—
duchenne muscular dystrophyEFO_0000429D020388—
Agency Specific
FDA
EMA
Expiration
Code
DEFLAZACORT, EMFLAZA, PTC THERAP
2026-06-07ODE-252
2024-02-09ODE-130
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB13: Deflazacort
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Muscular dystrophiesD009136EFO_0000757G71.02—2—15
Duchenne muscular dystrophyD020388EFO_0000429—2—1—14
Limb-girdle muscular dystrophiesD049288EFO_0000758G71.03——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Renal insufficiencyD051437—N191————1
Liver diseasesD008107EFO_0001421K70-K771————1
Hepatic insufficiencyD048550——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDeflazacort
INNdeflazacort
Description
Deflazacort is a corticosteroid hormone.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Identifiers
PDB—
CAS-ID14484-47-0
RxCUI—
ChEMBL IDCHEMBL1201891
ChEBI ID—
PubChem CID189821
DrugBankDB11921
UNII IDKR5YZ6AE4B (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Emflaza – PTC Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,992 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,920 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use